nodes	percent_of_prediction	percent_of_DWPC	metapath
Perflutren—Sevoflurane—CYP2A6—esophageal cancer	0.047	1	CrCbGaD
Perflutren—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.022	0.0231	CcSEcCtD
Perflutren—Swelling face—Capecitabine—esophageal cancer	0.0179	0.0188	CcSEcCtD
Perflutren—Peripheral coldness—Capecitabine—esophageal cancer	0.0179	0.0188	CcSEcCtD
Perflutren—Transient ischaemic attack—Capecitabine—esophageal cancer	0.0169	0.0178	CcSEcCtD
Perflutren—Haematoma—Capecitabine—esophageal cancer	0.0136	0.0143	CcSEcCtD
Perflutren—Respiratory distress—Capecitabine—esophageal cancer	0.0134	0.0141	CcSEcCtD
Perflutren—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.013	0.0137	CcSEcCtD
Perflutren—Hearing impaired—Cisplatin—esophageal cancer	0.0122	0.0128	CcSEcCtD
Perflutren—Pain—Carboplatin—esophageal cancer	0.012	0.0126	CcSEcCtD
Perflutren—Tongue disorder—Capecitabine—esophageal cancer	0.0117	0.0123	CcSEcCtD
Perflutren—Wheezing—Cisplatin—esophageal cancer	0.0112	0.0118	CcSEcCtD
Perflutren—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0111	0.0117	CcSEcCtD
Perflutren—Rash erythematous—Capecitabine—esophageal cancer	0.0111	0.0117	CcSEcCtD
Perflutren—Body temperature increased—Carboplatin—esophageal cancer	0.0111	0.0117	CcSEcCtD
Perflutren—Coagulopathy—Capecitabine—esophageal cancer	0.011	0.0115	CcSEcCtD
Perflutren—Myocardial ischaemia—Capecitabine—esophageal cancer	0.0106	0.0111	CcSEcCtD
Perflutren—Rigors—Capecitabine—esophageal cancer	0.0105	0.011	CcSEcCtD
Perflutren—Injection site pain—Capecitabine—esophageal cancer	0.0105	0.011	CcSEcCtD
Perflutren—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00945	0.00992	CcSEcCtD
Perflutren—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00927	0.00973	CcSEcCtD
Perflutren—Burning sensation—Methotrexate—esophageal cancer	0.00915	0.0096	CcSEcCtD
Perflutren—Hearing impaired—Capecitabine—esophageal cancer	0.00897	0.00941	CcSEcCtD
Perflutren—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00869	0.00912	CcSEcCtD
Perflutren—Neck pain—Capecitabine—esophageal cancer	0.00864	0.00907	CcSEcCtD
Perflutren—Injection site reaction—Capecitabine—esophageal cancer	0.00849	0.00891	CcSEcCtD
Perflutren—Influenza like illness—Capecitabine—esophageal cancer	0.00829	0.0087	CcSEcCtD
Perflutren—Face oedema—Cisplatin—esophageal cancer	0.00812	0.00852	CcSEcCtD
Perflutren—Cramp muscle—Cisplatin—esophageal cancer	0.00757	0.00794	CcSEcCtD
Perflutren—Abnormal vision—Capecitabine—esophageal cancer	0.00745	0.00781	CcSEcCtD
Perflutren—Sweating increased—Cisplatin—esophageal cancer	0.00708	0.00743	CcSEcCtD
Perflutren—Swelling—Capecitabine—esophageal cancer	0.00702	0.00737	CcSEcCtD
Perflutren—Hot flush—Capecitabine—esophageal cancer	0.00663	0.00695	CcSEcCtD
Perflutren—Menopausal symptoms—Capecitabine—esophageal cancer	0.00657	0.00689	CcSEcCtD
Perflutren—Atrial fibrillation—Capecitabine—esophageal cancer	0.00654	0.00686	CcSEcCtD
Perflutren—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00635	0.00666	CcSEcCtD
Perflutren—Conjunctivitis—Cisplatin—esophageal cancer	0.0063	0.00661	CcSEcCtD
Perflutren—Face oedema—Capecitabine—esophageal cancer	0.00598	0.00628	CcSEcCtD
Perflutren—Bradycardia—Cisplatin—esophageal cancer	0.00592	0.00621	CcSEcCtD
Perflutren—Cardiac arrest—Capecitabine—esophageal cancer	0.00589	0.00618	CcSEcCtD
Perflutren—Coma—Methotrexate—esophageal cancer	0.00581	0.00609	CcSEcCtD
Perflutren—Connective tissue disorder—Cisplatin—esophageal cancer	0.00572	0.006	CcSEcCtD
Perflutren—Dry skin—Capecitabine—esophageal cancer	0.00568	0.00596	CcSEcCtD
Perflutren—Visual impairment—Cisplatin—esophageal cancer	0.00561	0.00588	CcSEcCtD
Perflutren—Eye disorder—Cisplatin—esophageal cancer	0.00544	0.0057	CcSEcCtD
Perflutren—Tinnitus—Cisplatin—esophageal cancer	0.00542	0.00569	CcSEcCtD
Perflutren—Lymphadenopathy—Methotrexate—esophageal cancer	0.00541	0.00567	CcSEcCtD
Perflutren—Flushing—Cisplatin—esophageal cancer	0.0054	0.00566	CcSEcCtD
Perflutren—Cardiac disorder—Cisplatin—esophageal cancer	0.0054	0.00566	CcSEcCtD
Perflutren—Bronchospasm—Capecitabine—esophageal cancer	0.00527	0.00553	CcSEcCtD
Perflutren—Immune system disorder—Cisplatin—esophageal cancer	0.00525	0.00551	CcSEcCtD
Perflutren—Mediastinal disorder—Cisplatin—esophageal cancer	0.00524	0.0055	CcSEcCtD
Perflutren—Sweating increased—Capecitabine—esophageal cancer	0.00522	0.00548	CcSEcCtD
Perflutren—Arrhythmia—Cisplatin—esophageal cancer	0.0052	0.00545	CcSEcCtD
Perflutren—Erythema—Cisplatin—esophageal cancer	0.00506	0.00531	CcSEcCtD
Perflutren—Visual disturbance—Methotrexate—esophageal cancer	0.00487	0.00511	CcSEcCtD
Perflutren—Muscle spasms—Cisplatin—esophageal cancer	0.00487	0.00511	CcSEcCtD
Perflutren—Vision blurred—Cisplatin—esophageal cancer	0.00477	0.00501	CcSEcCtD
Perflutren—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00477	0.005	CcSEcCtD
Perflutren—Tremor—Cisplatin—esophageal cancer	0.00474	0.00498	CcSEcCtD
Perflutren—Ill-defined disorder—Cisplatin—esophageal cancer	0.0047	0.00493	CcSEcCtD
Perflutren—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00468	0.00491	CcSEcCtD
Perflutren—Conjunctivitis—Capecitabine—esophageal cancer	0.00464	0.00487	CcSEcCtD
Perflutren—Malaise—Cisplatin—esophageal cancer	0.00457	0.00479	CcSEcCtD
Perflutren—Leukopenia—Cisplatin—esophageal cancer	0.00453	0.00476	CcSEcCtD
Perflutren—Convulsion—Cisplatin—esophageal cancer	0.00439	0.0046	CcSEcCtD
Perflutren—Bradycardia—Capecitabine—esophageal cancer	0.00436	0.00458	CcSEcCtD
Perflutren—Myalgia—Cisplatin—esophageal cancer	0.00431	0.00452	CcSEcCtD
Perflutren—Haemoglobin—Capecitabine—esophageal cancer	0.00431	0.00452	CcSEcCtD
Perflutren—Rhinitis—Capecitabine—esophageal cancer	0.0043	0.00451	CcSEcCtD
Perflutren—Haemorrhage—Capecitabine—esophageal cancer	0.00429	0.0045	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00428	0.00449	CcSEcCtD
Perflutren—Hypoaesthesia—Capecitabine—esophageal cancer	0.00427	0.00448	CcSEcCtD
Perflutren—Discomfort—Cisplatin—esophageal cancer	0.00426	0.00447	CcSEcCtD
Perflutren—Pharyngitis—Capecitabine—esophageal cancer	0.00426	0.00447	CcSEcCtD
Perflutren—Connective tissue disorder—Capecitabine—esophageal cancer	0.00421	0.00442	CcSEcCtD
Perflutren—Oedema—Cisplatin—esophageal cancer	0.00413	0.00434	CcSEcCtD
Perflutren—Anaphylactic shock—Cisplatin—esophageal cancer	0.00413	0.00434	CcSEcCtD
Perflutren—Visual impairment—Capecitabine—esophageal cancer	0.00413	0.00434	CcSEcCtD
Perflutren—Nervous system disorder—Cisplatin—esophageal cancer	0.00405	0.00425	CcSEcCtD
Perflutren—Tachycardia—Cisplatin—esophageal cancer	0.00403	0.00423	CcSEcCtD
Perflutren—Skin disorder—Cisplatin—esophageal cancer	0.00401	0.00421	CcSEcCtD
Perflutren—Eye disorder—Capecitabine—esophageal cancer	0.00401	0.0042	CcSEcCtD
Perflutren—Tinnitus—Capecitabine—esophageal cancer	0.004	0.00419	CcSEcCtD
Perflutren—Hyperhidrosis—Cisplatin—esophageal cancer	0.00399	0.00419	CcSEcCtD
Perflutren—Flushing—Capecitabine—esophageal cancer	0.00398	0.00418	CcSEcCtD
Perflutren—Cardiac disorder—Capecitabine—esophageal cancer	0.00398	0.00418	CcSEcCtD
Perflutren—Eosinophilia—Methotrexate—esophageal cancer	0.00395	0.00414	CcSEcCtD
Perflutren—Angiopathy—Capecitabine—esophageal cancer	0.00389	0.00408	CcSEcCtD
Perflutren—Immune system disorder—Capecitabine—esophageal cancer	0.00387	0.00406	CcSEcCtD
Perflutren—Mediastinal disorder—Capecitabine—esophageal cancer	0.00386	0.00405	CcSEcCtD
Perflutren—Hypotension—Cisplatin—esophageal cancer	0.00386	0.00405	CcSEcCtD
Perflutren—Chills—Capecitabine—esophageal cancer	0.00385	0.00404	CcSEcCtD
Perflutren—Arrhythmia—Capecitabine—esophageal cancer	0.00383	0.00402	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00376	0.00395	CcSEcCtD
Perflutren—Erythema—Capecitabine—esophageal cancer	0.00373	0.00392	CcSEcCtD
Perflutren—Paraesthesia—Cisplatin—esophageal cancer	0.00371	0.00389	CcSEcCtD
Perflutren—Dyspnoea—Cisplatin—esophageal cancer	0.00368	0.00387	CcSEcCtD
Perflutren—Dysgeusia—Capecitabine—esophageal cancer	0.00365	0.00384	CcSEcCtD
Perflutren—Back pain—Capecitabine—esophageal cancer	0.00361	0.00379	CcSEcCtD
Perflutren—Muscle spasms—Capecitabine—esophageal cancer	0.00359	0.00377	CcSEcCtD
Perflutren—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00357	0.00374	CcSEcCtD
Perflutren—Pain—Cisplatin—esophageal cancer	0.00353	0.00371	CcSEcCtD
Perflutren—Vision blurred—Capecitabine—esophageal cancer	0.00352	0.00369	CcSEcCtD
Perflutren—Tremor—Capecitabine—esophageal cancer	0.0035	0.00367	CcSEcCtD
Perflutren—Ill-defined disorder—Capecitabine—esophageal cancer	0.00346	0.00363	CcSEcCtD
Perflutren—Conjunctivitis—Methotrexate—esophageal cancer	0.00346	0.00363	CcSEcCtD
Perflutren—Feeling abnormal—Cisplatin—esophageal cancer	0.00341	0.00357	CcSEcCtD
Perflutren—Malaise—Capecitabine—esophageal cancer	0.00337	0.00353	CcSEcCtD
Perflutren—Vertigo—Capecitabine—esophageal cancer	0.00335	0.00352	CcSEcCtD
Perflutren—Syncope—Capecitabine—esophageal cancer	0.00335	0.00351	CcSEcCtD
Perflutren—Leukopenia—Capecitabine—esophageal cancer	0.00334	0.00351	CcSEcCtD
Perflutren—Palpitations—Capecitabine—esophageal cancer	0.0033	0.00346	CcSEcCtD
Perflutren—Loss of consciousness—Capecitabine—esophageal cancer	0.00328	0.00344	CcSEcCtD
Perflutren—Body temperature increased—Cisplatin—esophageal cancer	0.00327	0.00343	CcSEcCtD
Perflutren—Cough—Capecitabine—esophageal cancer	0.00326	0.00342	CcSEcCtD
Perflutren—Hypertension—Capecitabine—esophageal cancer	0.00322	0.00338	CcSEcCtD
Perflutren—Haemoglobin—Methotrexate—esophageal cancer	0.00321	0.00337	CcSEcCtD
Perflutren—Haemorrhage—Methotrexate—esophageal cancer	0.00319	0.00335	CcSEcCtD
Perflutren—Arthralgia—Capecitabine—esophageal cancer	0.00318	0.00333	CcSEcCtD
Perflutren—Chest pain—Capecitabine—esophageal cancer	0.00318	0.00333	CcSEcCtD
Perflutren—Myalgia—Capecitabine—esophageal cancer	0.00318	0.00333	CcSEcCtD
Perflutren—Pharyngitis—Methotrexate—esophageal cancer	0.00317	0.00332	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00316	0.00331	CcSEcCtD
Perflutren—Discomfort—Capecitabine—esophageal cancer	0.00314	0.00329	CcSEcCtD
Perflutren—Dry mouth—Capecitabine—esophageal cancer	0.00311	0.00326	CcSEcCtD
Perflutren—Visual impairment—Methotrexate—esophageal cancer	0.00308	0.00323	CcSEcCtD
Perflutren—Oedema—Capecitabine—esophageal cancer	0.00305	0.0032	CcSEcCtD
Perflutren—Hypersensitivity—Cisplatin—esophageal cancer	0.00304	0.00319	CcSEcCtD
Perflutren—Shock—Capecitabine—esophageal cancer	0.003	0.00314	CcSEcCtD
Perflutren—Nervous system disorder—Capecitabine—esophageal cancer	0.00299	0.00313	CcSEcCtD
Perflutren—Eye disorder—Methotrexate—esophageal cancer	0.00298	0.00313	CcSEcCtD
Perflutren—Tinnitus—Methotrexate—esophageal cancer	0.00298	0.00312	CcSEcCtD
Perflutren—Tachycardia—Capecitabine—esophageal cancer	0.00297	0.00312	CcSEcCtD
Perflutren—Asthenia—Cisplatin—esophageal cancer	0.00296	0.00311	CcSEcCtD
Perflutren—Cardiac disorder—Methotrexate—esophageal cancer	0.00296	0.00311	CcSEcCtD
Perflutren—Skin disorder—Capecitabine—esophageal cancer	0.00296	0.0031	CcSEcCtD
Perflutren—Hyperhidrosis—Capecitabine—esophageal cancer	0.00294	0.00309	CcSEcCtD
Perflutren—Angiopathy—Methotrexate—esophageal cancer	0.0029	0.00304	CcSEcCtD
Perflutren—Immune system disorder—Methotrexate—esophageal cancer	0.00288	0.00303	CcSEcCtD
Perflutren—Mediastinal disorder—Methotrexate—esophageal cancer	0.00288	0.00302	CcSEcCtD
Perflutren—Chills—Methotrexate—esophageal cancer	0.00286	0.00301	CcSEcCtD
Perflutren—Hypotension—Capecitabine—esophageal cancer	0.00285	0.00299	CcSEcCtD
Perflutren—Diarrhoea—Cisplatin—esophageal cancer	0.00283	0.00297	CcSEcCtD
Perflutren—Erythema—Methotrexate—esophageal cancer	0.00278	0.00292	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00278	0.00291	CcSEcCtD
Perflutren—Paraesthesia—Capecitabine—esophageal cancer	0.00274	0.00287	CcSEcCtD
Perflutren—Dysgeusia—Methotrexate—esophageal cancer	0.00272	0.00286	CcSEcCtD
Perflutren—Dyspnoea—Capecitabine—esophageal cancer	0.00272	0.00285	CcSEcCtD
Perflutren—Back pain—Methotrexate—esophageal cancer	0.00269	0.00282	CcSEcCtD
Perflutren—Dyspepsia—Capecitabine—esophageal cancer	0.00268	0.00281	CcSEcCtD
Perflutren—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00263	0.00276	CcSEcCtD
Perflutren—Vomiting—Cisplatin—esophageal cancer	0.00263	0.00276	CcSEcCtD
Perflutren—Fatigue—Capecitabine—esophageal cancer	0.00263	0.00276	CcSEcCtD
Perflutren—Vision blurred—Methotrexate—esophageal cancer	0.00262	0.00275	CcSEcCtD
Perflutren—Rash—Cisplatin—esophageal cancer	0.00261	0.00273	CcSEcCtD
Perflutren—Pain—Capecitabine—esophageal cancer	0.0026	0.00273	CcSEcCtD
Perflutren—Dermatitis—Cisplatin—esophageal cancer	0.0026	0.00273	CcSEcCtD
Perflutren—Ill-defined disorder—Methotrexate—esophageal cancer	0.00258	0.00271	CcSEcCtD
Perflutren—Feeling abnormal—Capecitabine—esophageal cancer	0.00251	0.00263	CcSEcCtD
Perflutren—Malaise—Methotrexate—esophageal cancer	0.00251	0.00263	CcSEcCtD
Perflutren—Vertigo—Methotrexate—esophageal cancer	0.0025	0.00262	CcSEcCtD
Perflutren—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00249	0.00261	CcSEcCtD
Perflutren—Leukopenia—Methotrexate—esophageal cancer	0.00249	0.00261	CcSEcCtD
Perflutren—Nausea—Cisplatin—esophageal cancer	0.00245	0.00258	CcSEcCtD
Perflutren—Cough—Methotrexate—esophageal cancer	0.00242	0.00254	CcSEcCtD
Perflutren—Urticaria—Capecitabine—esophageal cancer	0.00242	0.00254	CcSEcCtD
Perflutren—Body temperature increased—Capecitabine—esophageal cancer	0.00241	0.00253	CcSEcCtD
Perflutren—Abdominal pain—Capecitabine—esophageal cancer	0.00241	0.00253	CcSEcCtD
Perflutren—Convulsion—Methotrexate—esophageal cancer	0.00241	0.00253	CcSEcCtD
Perflutren—Chest pain—Methotrexate—esophageal cancer	0.00237	0.00248	CcSEcCtD
Perflutren—Myalgia—Methotrexate—esophageal cancer	0.00237	0.00248	CcSEcCtD
Perflutren—Arthralgia—Methotrexate—esophageal cancer	0.00237	0.00248	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00235	0.00247	CcSEcCtD
Perflutren—Discomfort—Methotrexate—esophageal cancer	0.00234	0.00245	CcSEcCtD
Perflutren—Anaphylactic shock—Methotrexate—esophageal cancer	0.00227	0.00238	CcSEcCtD
Perflutren—Hypersensitivity—Capecitabine—esophageal cancer	0.00224	0.00235	CcSEcCtD
Perflutren—Nervous system disorder—Methotrexate—esophageal cancer	0.00222	0.00233	CcSEcCtD
Perflutren—Skin disorder—Methotrexate—esophageal cancer	0.0022	0.00231	CcSEcCtD
Perflutren—Hyperhidrosis—Methotrexate—esophageal cancer	0.00219	0.0023	CcSEcCtD
Perflutren—Asthenia—Capecitabine—esophageal cancer	0.00219	0.00229	CcSEcCtD
Perflutren—Pruritus—Capecitabine—esophageal cancer	0.00216	0.00226	CcSEcCtD
Perflutren—Hypotension—Methotrexate—esophageal cancer	0.00212	0.00222	CcSEcCtD
Perflutren—Diarrhoea—Capecitabine—esophageal cancer	0.00208	0.00219	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00207	0.00217	CcSEcCtD
Perflutren—Paraesthesia—Methotrexate—esophageal cancer	0.00204	0.00214	CcSEcCtD
Perflutren—Dyspnoea—Methotrexate—esophageal cancer	0.00202	0.00212	CcSEcCtD
Perflutren—Dizziness—Capecitabine—esophageal cancer	0.00201	0.00211	CcSEcCtD
Perflutren—Dyspepsia—Methotrexate—esophageal cancer	0.002	0.00209	CcSEcCtD
Perflutren—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00196	0.00205	CcSEcCtD
Perflutren—Fatigue—Methotrexate—esophageal cancer	0.00195	0.00205	CcSEcCtD
Perflutren—Pain—Methotrexate—esophageal cancer	0.00194	0.00203	CcSEcCtD
Perflutren—Vomiting—Capecitabine—esophageal cancer	0.00194	0.00203	CcSEcCtD
Perflutren—Rash—Capecitabine—esophageal cancer	0.00192	0.00202	CcSEcCtD
Perflutren—Dermatitis—Capecitabine—esophageal cancer	0.00192	0.00201	CcSEcCtD
Perflutren—Headache—Capecitabine—esophageal cancer	0.00191	0.002	CcSEcCtD
Perflutren—Feeling abnormal—Methotrexate—esophageal cancer	0.00187	0.00196	CcSEcCtD
Perflutren—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00185	0.00195	CcSEcCtD
Perflutren—Nausea—Capecitabine—esophageal cancer	0.00181	0.0019	CcSEcCtD
Perflutren—Urticaria—Methotrexate—esophageal cancer	0.0018	0.00189	CcSEcCtD
Perflutren—Body temperature increased—Methotrexate—esophageal cancer	0.00179	0.00188	CcSEcCtD
Perflutren—Abdominal pain—Methotrexate—esophageal cancer	0.00179	0.00188	CcSEcCtD
Perflutren—Hypersensitivity—Methotrexate—esophageal cancer	0.00167	0.00175	CcSEcCtD
Perflutren—Asthenia—Methotrexate—esophageal cancer	0.00163	0.00171	CcSEcCtD
Perflutren—Pruritus—Methotrexate—esophageal cancer	0.0016	0.00168	CcSEcCtD
Perflutren—Diarrhoea—Methotrexate—esophageal cancer	0.00155	0.00163	CcSEcCtD
Perflutren—Dizziness—Methotrexate—esophageal cancer	0.0015	0.00157	CcSEcCtD
Perflutren—Vomiting—Methotrexate—esophageal cancer	0.00144	0.00151	CcSEcCtD
Perflutren—Rash—Methotrexate—esophageal cancer	0.00143	0.0015	CcSEcCtD
Perflutren—Dermatitis—Methotrexate—esophageal cancer	0.00143	0.0015	CcSEcCtD
Perflutren—Headache—Methotrexate—esophageal cancer	0.00142	0.00149	CcSEcCtD
Perflutren—Nausea—Methotrexate—esophageal cancer	0.00135	0.00141	CcSEcCtD
